SIA
ALNY icon

SkyView Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

SkyView Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-509
Closed -$4K – 581
2021
Q4 		$4K Sell
509
-724
-59% -$135K ﹤0.01% 546
2021
Q3 		$233K Buy
+1,233
New +$231K 0.07% 314

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SkyView Investment Advisors's ALNY Position: Q1 2022 in Review

SkyView Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 509 shares — an estimated $4K sold.

SkyView Investment Advisors first reported a position in ALNY in Q3 2021 and held it in 2 quarters. The position peaked at $233K in Q3 2021. 443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • SkyView Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SkyView Investment Advisors sold 509 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $4K.
  • SkyView Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • SkyView Investment Advisors's Alnylam Pharmaceuticals position peaked at $233K in Q3 2021.
  • 443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on SkyView Investment Advisors's 13F filing for Q1 2022, filed 17 May 2022.